Emicizumab in the Treatment of Hemophilia A. Characteristics and clinical application

Introduction: Hemophilia A is an inherited bleeding disorder caused by a congenital deficiency of factor VIII. It is characterized by a tendency for prolonged and excessive bleeding, both spontaneous and trauma-induced. The treatment of hemophilia A involves the use of factor VIII replacement thera...

Cijeli opis

Bibliografski detalji

Glavni autori:	Ilona Bednarek, Sylwia Lach, Aleksandra Kowalczyk, Adrian Pączek, Paweł Dyczek, Julia Hofman, Wiktoria Staniszewska, Olaf Jadanowski, Karol Seweryn Błąd
Format:	Artigo
Jezik:	Inglês
Izdano:	Kazimierz Wielki University 2025-11-01
Serija:	Journal of Education, Health and Sport
Teme:	Hemophilia A emicizumab pharmacokinetics ABR HAVEN trials factor VIII
Online pristup:	https://apcz.umk.pl/JEHS/article/view/66759
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!